Strong Q1 2026 results with 16% YoY revenue growth, 26% growth in commercial CGT revenue, record 766 supported clinical trials, improved adjusted EBITDA ($2.2M improvement YoY), solid gross margins (45.8%), and raised full-year revenue guidance to $192-196 million. Strategic expansion plans with new Global Supply Chain Centers in Paris (Q3) and Santa Ana (Q4) demonstrate confidence in future growth.
The company launched an innovative, award-winning product that addresses longstanding industry challenges. Leadership describes it as 'transformative' and 'a step forward into the future,' with potential to become the new standard in the industry. The product offers significant operational and infrastructure advantages over legacy systems.
Articles that tag CYRX but are mainly about other companies.
Cryoport specializes in cold chain logistics for biopharmaceuticals, directly benefiting from the market's projected 15.51% CAGR growth and increasing demand for specialized cold chain infrastructure and validated temperature-controlled solutions.
Supporting 701 global clinical trials with 81 in Phase 3, backed 19 commercial therapies as of December 2024, and repurchased $185 million in convertible notes to fund expansion amid record regulatory approvals.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
